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Background: Acquired resistance towards apoptosis is a hallmark of cancer. Elimination of cells bearing
activated oncogenes or stimulation of tumor suppressor mediators may provide a selection pressure to
overcome resistance. KC-53 is a novel biyouyanagin analogue known to elicit strong anti-inflammatory and
anti-viral activity. The current study was designed to evaluate the anticancer efficacy and molecular mechanisms of
KC-53 against human cancer cells.
Methods: Using the MTT assay we examined initially how KC-53 affects the proliferation rates of thirteen
representative human cancer cell lines in comparison to normal peripheral blood mononuclear cells (PBMCs)
and immortalized cell lines. To decipher the key molecular events underlying its mode of action we selected
the human promyelocytic leukemia HL-60 and the acute lymphocytic leukemia CCRF/CEM cell lines that were
found to be the most sensitive to the antiproliferative effects of KC-53.
Results: KC-53 promoted rapidly and irreversibly apoptosis in both leukemia cell lines at relatively low concentrations.
Apoptosis was characterized by an increase in membrane-associated TNFR1, activation of Caspase-8 and proteolytic
inactivation of the death domain kinase RIP1 indicating that KC-53 induced mainly the extrinsic/death receptor
apoptotic pathway. Regardless, induction of the intrinsic/mitochondrial pathway was also achieved by Caspase-8
processing of Bid, activation of Caspase-9 and increased translocation of AIF to the nucleus. FADD protein knockdown
restored HL-60 and CCRF/CEM cell viability and completely blocked KC-53-induced apoptosis. Furthermore, KC-53
administration dramatically inhibited TNFα-induced serine phosphorylation on TRAF2 and on IκBα hindering therefore
p65/NF-κΒ translocation to nucleus. Reduced transcriptional expression of pro-inflammatory and pro-survival p65 target
genes, confirmed that the agent functionally inhibited the transcriptional activity of p65.
Conclusions: Our findings demonstrate, for the first time, the selective anticancer properties of KC-53 towards
leukemic cell lines and provide a detailed understanding of the molecular events underlying its dual anti-proliferative
and pro-apoptotic properties. These results provide new insights into the development of innovative and targeted
therapies for the treatment of some forms of leukemia.
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Apoptosis deregulation occurs commonly in hematological
malignancies and has been connected to cancer pathogen-
esis, progression and chemoresistance [1]. The two main
effector cascades that are involved in apoptosis are the in-
trinsic (mitochondrial), and the extrinsic (death receptor)
pathways [2]. Alterations affecting key molecules of these
pathways such as Bcl-2, p53 and the nuclear factor κΒ
(NF-κB) lead to accumulation of malignant cells. Among
the latter, NF-κB promotes the transcription of genes en-
coding proteins involved in the suppression of cell death
by both the intrinsic and the extrinsic pathway [3, 4]. Thus,
elevation in NF-κB activity can increase cellular resistance
to apoptosis.
The extrinsic pathway of apoptosis is initiated by en-
gagement of cell surface receptors with specific ligands.
The tumor necrosis factor receptor 1 (TNFR1) pos-
sesses important roles in many cellular responses. Once
TNFR1 is stimulated by its ligand (TNFα), two com-
plexes with opposing effects on cell fate can be formed:
a pro-survival and a pro-apoptotic complex. In the
presence of phosphorylated TNF receptor-associated
factor 2 (TRAF2), pro-survival NF-κΒ activation domi-
nates over pro-apoptotic Caspase-8 activation. TRAF2
phosphorylation, occurring on Ser 11, promotes receptor-
interacting protein 1 (RIP1) ubiquitination, facilitating the
recruitment and activation of the downstream IκB kinase
complex (IKK). This leads to NF-κΒ activation [5, 6] and
concurrently preventing RIP1 from interacting with
Fas-associated death domain (FADD) protein and pro-
caspase-8 [7, 8]. Under pro-apoptotic conditions,
RIP1 dissociates from TRAF2 and binds to the
FADD/Caspase-8 complex. Active Caspase-8 cleaves
and inactivates RIP1 initiating the extrinsic pathway
of apoptosis [9, 10].
Agents that trigger the extrinsic pathway are particu-
larly intriguing, since nearly all anti-cancer drugs utilize
the intrinsic pathway to induce apoptosis, and cells often
become resistant by accumulating defects in this path-
way (Reviewed in [11]). Consistent with this notion, de-
letions or mutations of p53 [12, 13] or over-expression
of Bcl-2 [14, 15] and NF-κB [16] are common in acute
myelocytic leukemia (AML) and acute lymphocytic
leukemia (ALL) resulting in resistance to drugs that in-
duce apoptosis through the intrinsic pathway. Conse-
quently, the development of agents that trigger the
extrinsic pathway of apoptosis is a promising approach
for drug development against this disease [17–19].
Clinical trials aiming to evaluate the anticancer effi-
cacy of TNF family members originated with the use
of human TNFα mainly in advanced solid cancers
[20, 21]. Recombinant human TNFα (rhTNFα) has
been tested as a systemic treatment in several clinical
trials and used as both a single agent and incombination with chemotherapeutics. Even though
rhTNFα was proven as an effective anticancer agent
in preclinical studies, these attempts were disappoint-
ing as clinical activity was rarely obtained; rhTNFα
was unable to trigger apoptosis via TNFR1 unless the
initial NF-κB pathway was blocked [22]. In addition,
rhTNFα was highly cytotoxic towards hepatocytes
causing severe side effects and lacked of evidence for
therapeutic benefit [20]. Subsequently, for the devel-
opment of rational death receptor-targeted therapy it
is important to discover agents able to activate the
death receptors without triggering the NF-κB cascade.
Biyouyanagins are sesquiterpene spiro-lactones iso-
lated from the plant Hypericum chinense with selective
anti-virus and anti-inflammatory properties [23–26].
Our recent research around the molecular space of
biyouyanagins structure revealed a new promising lead
molecule; the post-photocycloaddition modified analogue
53 (Fig. 1a) [26]. Specifically, in THP-1 human macro-
phage cells, KC-53 inhibited the production and secretion
of cytokines IL-6, IL-1β, and TNFα without affecting the
production of cytokines IL-1α no 1β and IL-8 [26].
Since KC-53 was found to possess anti-inflammatory
properties, and taking into consideration the key role of
NF-κB in the inflammatory response, we postulated
that, KC-53 may exhibit anticancer effects mediated
through its interference with the TNFR1/NF-κB path-
way. Our results show that among 13 cell lines tested,
HL-60 (p53−/−) and CCRF/CEM (p53mut) are espe-
cially susceptible to the KC-53 pro-apoptotic effects
due to, predominantly, activation of TNFR1 and the
concomitant inhibition of p65/NF-κB translocation to
the nucleus. The properties of KC-53, unveiled here,
are consistent with those of a promising targeted thera-
peutic that could be especially effective in the treatment
of some forms of leukemia that do not respond to
drugs inducing only the intrinsic pathway of apoptosis.
Methods
Synthesis of KC-53
KC-53 was prepared by K.C. Nicolaou laboratory as pre-
viously described [26].
Chemicals and reagents
FBS, Horse Serum, antibiotic/antimycotic, EGF, insulin,
Cholera Toxin, Hydrocortizone, L-Glutamine, HEPES,
Sodium Pyruvate and media used in cell culture were
purchased from Gibco, Invitrogen (Carlsbad, California).
Etoposide and Doxorubicin were purchased from Tocris
(Bristol, UK). The pan caspase inhibitor z.vad.fmk
was purchased from Sigma (St. Louis, Missouri). TNFα,
and PS-341 (Bortezomib) were purchased from Merck
Millipore (Darmstadt, Germany). Protease inhibitor
cocktail was obtained from Roche (Indianapolis, IN).
Fig. 1 KC-53 chemical structure and its antiproliferative effects on a
panel of cell lines and PBMCs. a Chemical structure of KC-53
molecule. b Cells were exposed to 5 μΜ of KC-53 for 48 h and
cell survival was determined using the MTT assay. Cell viability is
expressed as percentage of survival in vehicle treated cells. The
results represent the mean ± SEM of three replicates and are
representative of three different experiments. (*p value <0.05,
**p value <0.01, ***p value <0.001)
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TNFR2, AIF, FADD, p-IκBα, p-TRAF2, p65/NF-κB and
α-Tubulin antibodies were purchased from Cell Signal-
ing Technology (Danvers, Massachusetts). Total TRAF2,
total IκBα, Histone H3, EGFR, and GAPDH antibodies
were obtained from Santa Cruz Biotechnology (Heidel-
berg, Germany). All other reagents were purchased from
Sigma (St. Louis, Missouri).
Cell culture
MCF-7, MDA-MB-231-TXSA, STSA, LoVo, Ishikawa
and KHOS cells were cultured in DMEM supplemented
with 10 % FBS, 1 % antibiotic/antimycotic and 4 mM L-
Glutamine, PC-3, A-549, Jurkat, HL-60, CCRF/CEM,Raji and Daudi in RPMI supplemented with 10 %
FBS, 1 % antibiotic/antimycotic and 4 mM L-Glutam-
ine, and MCF-12F in DMEMF12 supplemented with
20 ng/mL EGF, 100 ng/mL Cholera Toxin, 500 ng/mL
Hydrocortizone, 10 μg/mL insulin, 5 % Horse Serum
and 1 % antibiotic/antimycotic. All cell lines were ob-
tained from the American Type Culture Collection
(ATCC) (Manassas, VA).
Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
Human normal PBMCs were isolated from hepari-
nised venous blood samples by density gradient
centrifugation method using Ficol-Histopaque (Sigma,
St. Louis, Missouri). Briefly, the heparinised blood
was layered on Histopaque in the ratio of 1:1 and
subjected to centrifugation at 2,000 rpm for 30 min.
The white layer representing PBMCs was aspirated
out and transferred into sterile centrifuge tubes. The
suspension of cells was then washed twice and cul-
tured in RPMI supplemented with 10 % FBS, 1 %
antibiotic/antimycotic and 4 mM L-Glutamine. After
24 h incubation at 37 °C non adherent cells (B- and
T-cells) were collected for use in the experiments.
Written informed consent was obtained from the do-
nors of PBMCs and ethical approval was obtained
from the Cyprus National Bioethics Committee in ac-
cordance with the Declaration of Helsinki.
Proliferation assay
A total of 1 × 104 cells were seeded per well of a 96-well
plate in medium supplemented with the different con-
centrations of KC-53 or vehicle control, for the time pe-
riods described in the figure legends. At the end of each
incubation period, MTT at a final concentration of
0.5 mg/mL was added to the medium and left to be me-
tabolized for 3 h. Following that, plates were centrifuged
at 1,500 rpm for 5 min. The medium was removed and
DMSO was added in each well and incubated with gen-
tly shaking for 20 min. The absorbance measured at
570 nm, was proportional to the number of viable cells
per well.
Cell cycle analysis
Cells were added at a concentration of 1 × 106 cells
per a 100 mm plate and treated with KC-53 for indi-
cated times at 37 °C. Following incubation, samples
were harvested by centrifugation at 1,500 rpm for
5 min at 4 °C and washed with PBS. Cells were fixed
with 70 % ethanol and stained with propidium iodide
(PI) staining solution (0.2 mg/mL RNase A, 0.01 mg/mL
PI). Samples were analyzed for DNA content using the
Guava EasyCyte™ flow cytometer and the GuavaSoft ana-
lysis software (Millipore, Watford, UK).
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Cells were seeded at a concentration of 1 × 105 cells per
a 60 mm plate and treated with KC-53 or Doxorubicin
(Dox) as indicated. Cells were harvested and stained
using Annexin-V Alexa Fluor® 488/PI, as described by
the Tali™ apoptosis kit (Life Technologies, Carlsbad, CA).
Cell viability, death and apoptosis were evaluated using
the Tali™ Image-based Cytometer (Life Technologies,
Carlsbad, CA). The Annexin-V positive/PI negative cells
were recognized as early apoptotic cells by the cytometer
software whereas the Annexin-V positive/PI positive
cells were identified as late apoptotic/dead cells.
Cell death detection ELISA
Cells were added at a concentration of 1 × 104 cells
per well of a 96-well plate and treated with KC-53 in
the present or absence of pan-caspase inhibitor,
z.vad.fmk as indicated. The quantification of mono- and
oligo-nucleosomes present in the cytoplasm of apoptotic
cells was performed using the Cell Death ElisaPLUS
Apoptosis Kit according to the manufacturer’s instructions
(Roche, Indianapolis, IN). The specific Enrichment Factor
of mono- and oligo-nucleosomes is expressed as absorb-
ance of treated cells to absorbance of corresponding nega-
tive control.
Caspase-8 enzymatic activity
Caspase-8 activity was measured using fluorogenic sub-
strate IETD-AFC (KHZ0052) according to the manufac-
turer’s instructions (Invitrogen, California, USA). In
brief, PBS-washed cell pellets were resuspended in Lysis
buffer and incubated on ice for 10 min. Lysate was then
centrifuged at 11,000 rpm for 5 min at 4 °C and
supernatant-cytosolic fraction was collected. Substrate at
50 μΜ final concentration was added to 50 μg of cyto-
solic extract in each well of a 96-well plate followed by
incubation for 1 h at 37 °C. Caspase activity was mea-
sured by monitoring the release of fluorigenic AFC using
an auto-microplate reader (excitation 400 nm, emission
505 nm, slit width 15). Fold-increase in Caspase-8 activ-
ity was determined by direct comparison to the level of
the uninduced control.
Preparation of nuclear and cytosolic extracts
A total of 2 × 107 cells were treated as indicated. After
incubation, cells were harvested by centrifugation at
1,500 rpm for 5 min at 4 °C and washed with ice cold
PBS. Cells were resuspended in ice cold Lysis buffer
(10 mM HEPES, 1 mM EDTA, 60 mM KCl, 0.5 % (v/v)
NP-40, 1 mM DTT, 1 mM PMSF, protease inhibitors,
pH 7.9) and incubated at 4 °C for 10 min. Samples were
then centrifuged at 12,000 g for 10 min at 4 °C and
supernatant (cytosolic extract) was collected. Cytosolic
fraction was further processed by centrifugation at14,000 g, for 10 min at 4 °C. Supernatant was recollected
and stored at −80 °C. Pellet was washed twice with
Washing buffer (10 mM HEPES, 1 mM EDTA, 60 mM
KCl, 1 mM DTT, 1 mM PMSF, protease inhibitors,
pH 7.9) and Nuclear suspension buffer (250 mM Tris-
Hydrochloride, 60 mM KCl, 1 mM DTT, 1 mM PMSF,
protease inhibitors, pH 7.8) was added to each sample.
Nucleus lysis was achieved by sonication (4 bursts, at
amplitude 4, for 4 sec with 2 min cooling between
bursts) with the use of an ultrasonic microprocessor and
clarified by centrifugation at 10,000 g for 15 min at 4 °C.
Supernatant (nuclear extract) was collected and stored
at −80 °C.
Quantitative real-time reverse transcription PCR (RT-qPCR)
Total RNA was extracted with Trizol reagent (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol.
cDNA was synthesized with random and oligo (dT)
primers using the PrimeScript Reverse Transcriptase
(TaKaRa Bio. Inc, Dalian, China). Primers were designed
using Primer3 and are listed in Additional file 1. Real-
Time PCR was performed using the BioRad CFX96
Real-Time System and the SYBR Green PCR Master
Mix (Kapa Biosystems, Massachusetts) according to
the manufacturer’s instructions. The PCR products
were normalized to those obtained from human
GAPDH mRNA amplification.
RNA interference
FADD siRNA (sc-35352) and negative control siRNA
(sc-37007) were purchased from Santa Cruz Biotechnol-
ogy. For the transfection procedure, HL-60 and CCRF/
CEM cells were seeded at a concentration of 4x105/mL
per well of a 12-well plate and FADD siRNA or control
siRNA were transfected with the use of LipofetamineTM
2000 (Invitrogen, Carlsbad, CA) and siTransfection Re-
agent (Santa Cruz Biotechnology, Heidelberg, Germany)
correspondingly according to the manufacturer’s instruc-
tions. The final concentration of siRNA in each well was
100 nM.
Immunoblotting
Cells were treated as indicated and lysed with RIPA
buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5
μΜ EGTA, 140 mM NaCl, 1 % Triton X-100, 0.1 %
SDS, protease inhibior cocktail, phosphatase inhibi-
tors; 5 mM NaF, 1 mM Na3VO4). For preparation of
membrane and cytosolic extracts, the Subcellular Pro-
tein Fractionation Kit for Cultured Cells (PI-78840)
was used according to the manufacturer’s instructions
(Thermo Scientific, Rockford) with slight modifica-
tions. The total protein concentration was determined
using Bradford reagent. Protein lysates were separated
by electrophoresis on a 8–12 % SDS-PAGE gels and
Table 1 IC50 values of KC-53 in vitro antiproliferative activity in
human cell lines
Cell Line IC50 (μΜ)
HL-60 2.3 ± 1.0
CCRF/CEM 2.4 ± 1.0
LoVo 2.5 ± 1.6
Jurkat 3.4 ± 1.7
Daudi 3.8 ± 1.9
KHOS 5.0 ± 2.0
MDA-MB-231-TXSA 8.0 ± 3.5
STSA 15.4 ± 5.2
MCF-12 F 15.5 ± 5.5
MCF-7 16.0 ± 3.5
Raji 16.3 ± 6.1
A549 19.1 ± 10
Ishikawa 21.1 ± 10
PC-3 33.6 ± 9.7
PBMCs >60
Cells were incubated with increasing concentrations of KC-53 (0–60 μΜ) for
48 h. The IC50 values were calculated from MTT viability curves. The data are
expressed as the mean ± SD of three independent experiments performed
in triplicate
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Westerns blots were probed with the specific antibodies
and protein bands were detected by enhcaned chemi-
luminescence. Anti-GAPDH, anti-Histone H3, anti-α-
Tubulin and anti-EGFR monoclonal antibodies were used
as loading controls. The intensity values from the densi-
tometry analysis of Western blots were normalized against
EGFR, α-Tubulin or Histone H3 using ImageJ analysis
software (NIH). Intensity values were expressed as fold
change compared to control.
Statistical analysis
Results for continuous variables were presented as Mean
±Standard Error. Two- group differences in continuous
variables were assessed by the unpaired T-test. P-values
are two-tailed with confidence intervals 95 %. Statistical
analysis was performed by comparing treated samples
with vehicle controls. All statistical tests were conducted
using Prism software version 5.0 (Graphpad, San Diego,
California).
Results
KC-53 inhibits the proliferation of human cancer cell lines
The effect of KC-53 on tumor cell viability was initially
determined in a series of human cancer cell lines to
identify those that are the most sensitive to the agent.
Thus, we have determined the effects of KC-53 on the
viability of human breast (MCF-7, MDA-MB-231-
TXSA), lung (A-549), prostate (PC-3), colon (LoVo),
endometrial (Ishikawa), osteosarcoma (KHOS), gastric
(STSA), leukemia (Jurkat, HL-60, CRF/CEM) and
lymphoma (Raji, Daudi) tumorigenic cells. PBMCs and
“normal” immortalized MCF-12 F breast cells were used
as control cell lines. The HL-60 (AML/APL) and CCRF/
CEM (ALL) cell lines were the most sensitive as deter-
mined by the IC50 at 48 h (Table 1). Importantly, the
normal PBMCs and the immortalized MCF-12 F cells
were relatively resistant to the anti-proliferative effects
of the compound (Fig. 1b). KC-53 reduced cancer cell
viability in a dose-depended manner in all cell lines with
a maximum effect on the most sensitive cell lines ran-
ging from 5 to 10 μM (Additional file 2). The two most
sensitive cell lines were selected to further investigate
the anti-proliferative mechanism of KC-53.
KC-53 was found to reduce HL-60 and CCRF/CEM
cell growth in a dose- and time- depended manner pro-
ducing maximum reduction in cell viability at 10 μM in
HL-60 and at 5 μM in CCRF/CEM (Fig. 2a). It became
apparent from these growth response curves that the ef-
fect of the agent was almost immediate. To follow-up on
this observation, we examined the possibility that the ef-
fects of KC-53 were irreversible. Towards this objective,
we exposed the cells to KC-53 for 1, 3, 6 and 12 h
followed by a post-treatment recovery period in agent-free medium for 48 h. In both cell lines viability was
only partially restored when KC-53 was removed after
1 or 3 h of treatment (Fig. 2b). Treatments for 6 and
12 h produced a similar effect to that of continuous
exposure. Thus, after 6 h of treatment the compound
produced an irreversible inhibition of cell growth.
The observed growth inhibitory effect of KC-53 in
leukemic cells was not accompanied by any significant
changes in the distribution of cell cycle phases as de-
termined by flow cytometry (Fig. 2c). However, after
12 and 24 h of treatment there was an increase in
Sub-G1 phase, indicative of apoptosis.
KC-53 induces apoptosis in HL-60 and CCRF/CEM cells
The possible induction of apoptosis by KC-53 was ini-
tially evaluated with the use of Annexin-V-FITC/PI
assay. As indicated in Fig. 3a, within 12 h of treatment
there was a significant increase in the early apoptotic
fraction of both cell lines. After 24 h of treatment,
26.5 % of HL-60 and 27.5 % of CCRF/CEM cells were
characterized as early apoptotic whereas, 15 % of cells
from both cell lines were in the late apoptotic stage.
Apoptotic induction was further analyzed by the
ELISA cell death kit which enables the detection of
mono- and oligo-released nucleosomes in the cytosol.
KC-53 induced substantial DNA fragmentation in HL-60
cells (7.4 fold increase compared to the control) and in
CCRF/CEM cells (6.4 fold increase compared to the
control) (Fig. 3b (i)). In the presence of the pan caspase
Fig. 2 Effects of KC-53 on leukemic cellular proliferation and cell cycle progression. a Cells were treated with increasing concentrations of KC-53
for the times indicated. Cell viability determined by the MTT assay, is expressed as percentage of survival in comparison to vehicle treated
controls. b Cells were exposed to 0 or 5 μΜ of KC-53 followed by removal of the agent after 1, 3, 6 or 12 h incubation and cell viability
was determined after 48 h recovery in drug-free medium. A positive control, where KC-53 was not removed, is shown for comparison.
c Cells were treated with 0 or 5 μM KC-53 for the times indicated and cell cycle was assessed by FACS analysis. The results represent the mean ± SEM of
three replicates and are representative of three different experiments. (*p value <0.05, **p value <0.01, ***p value <0.001, ###p value <0.001)
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cantly reduced in HL-60 cells and it was fully abolished
in CCRF/CEM cells. These data suggest that activation
of caspase cascades is predominantly involved in KC-53-
induced apoptosis. DNA analysis was also performed
with the Comet Assay where KC-53-induced DNA dam-
age was evident within 9 h of treatment (Additional file
3) and was exclusively attributed to apoptosis as no cel-
lular ROS production was detected (Additional file 4).
Even though co-incubation of KC-53 with z.vad.fmk
restored DNA fragmentation, it did not fully restore the
viability of cells (Fig. 3b (ii)). HL-60 viability increased
from 43 to 60 % in the presence of z.vad.fmk while no
alterations were observed in the viability of CCRF/CEM.
These findings indicate that inhibition of cell prolifera-
tion by KC-53 might be mediated by both caspase
-dependent (CD) and -independent (CID) programmed
cell death in a cell-context-specific manner.KC-53 promotes apoptosis through activation of the
TNFR1 signaling pathway
To fully characterize the apoptotic pathway being in-
duced by KC-53, we monitored the potential activa-
tion of caspases and any changes in the membrane
death receptor levels. In both HL-60 and CCRF/CEM
cell lines an increase in membrane-associated TNFR1
was evident with KC-53 treatment for 6 up to 24 h
(Fig. 4a). The corresponding protein levels of TNFR2
were not significantly affected by the treatment
(Fig. 4a). The levels of death receptors FAS, DR3 and
DR5, decoy receptor DcR3 as well as those of adaptor
proteins FADD and TRADD remained relatively un-
affected (Additional file 5).
The increase in TNFR1 levels was accompanied by
strong activation and detection of the cleaved 43/41 kDa
forms of Caspase-8 (C-Casp8) and proteolytic inactiva-
tion of RIP1 (C-RIP1) (Fig. 4b (i)) indicating that the
Fig. 3 Effects of KC-53 on cell apoptosis and DNA integrity. a Cells were treated with 0 or 5 μΜ KC-53 for the indicated time points and apoptosis
was assessed with Annexin-V/PI staining. Statistical significance was determined by comparing treated samples with the corresponding population of
the vehicle control. For comparison, Doxorubicin (Dox) at 0.5 μΜ was used as positive control. b (i) Cells were treated with 0 or 5 μΜ
KC-53 in the presence or absence of 20 μM z.vad.fmk for 24 h. The presence of nucleosomes in the cytoplasm was determined with the
ELISA cell death detection kit and is expressed as Enrichment Factor. Etoposide (Eto) at 5 μΜ was used as positive control. (ii) Cells were
treated with vehicle control or 5 μΜ KC-53 in the presence or absence of 20 μM z.vad.fmk, as shown, for 24 h. Cell viability was assessed
with the MTT assay. The results represent the mean ± SEM of two replicates and are representative of three independent experiments.
(*p value <0.05, **p value <0.01, ***p value <0.001, #p value <0.05, ###p value <0.001)
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between the extrinsic and the intrinsic pathways is well
established and occurs though Caspase-8 cleavage and
activation of the pro-apoptotic protein Bid [27, 28]. To
investigate this scenario we determined the expression
levels of cleaved/truncated Bid (tBid). KC-53 administra-
tion resulted in the detection of the 15 kDa tBid frag-
ment in both cell lines (Fig. 4b (i)). The cleavage of Bid
occurred in the early stage of apoptosis (6 h) parallel
with Caspase-8 activation. In both cell lines the amount
of the 15 kDa peptide was constant during the time
course of apoptosis and became undetectable after 24 h,
possibly due to further degradation.
Caspase-8 enzymatic activity was verified with the use
of fluorometric protease assay kit, in the presence or ab-
sence of z.vad.fmk. KC-53 produced a significant in-
crease of Caspase-8 activity within 4 h of treatment.
Specifically, after 12 h there was a 6.6 fold increase of
Caspase-8 activity in HL-60 cells and an 8 fold increase
in CCRF/CEM cells (Fig. 4b (ii)). The effects of KC-53
on Caspase-8 activity were fully reversed by z.vad.fmk in
both cell lines.
To further evaluate the apoptotic effect of KC-53, we
monitored the expression of the executor Caspases, −3and −7 and their substrate PARP1. KC-53 markedly in-
creased the active, cleaved forms of Caspases −3 (C-
Casp3; 19/17 kDa) and −7 (C-Casp7; 20 kDa), which
was evident within 6 h of treatment and persisted for
24 h post-treatment (Fig. 4c (i)). Caspase activation
was accompanied by a decrease in the levels of the
full length 116 kDa PARP1 and appearance of the
cleaved 89 kDa form (C-PARP1) (Fig. 4c (i)). Simi-
larly, KC-53 induced activation of the initiator
Caspase-9 (C-Casp9; 37/35 kDa) (Fig. 4c (i)) and
translocation of apoptosis inducing factor, AIF from
the cytosol to the nucleus (Fig. 4c (ii)). In HL-60
cells, the nuclear levels of AIF increased up to two
fold and in CCRF/CEM up to 2.8 fold following 6 h
of treatment (Fig. 4c (ii)). Both Caspase-9 activation
and AIF release are characteristics of mitochondrial
outer membrane permeabilization (MOMP) apparently
induced by tBid. These findings support the involve-
ment of mitochondrial-mediated intrinsic pathway in
the induction of apoptosis by KC-53. Furthermore, as
AIF is a mediator of CID apoptotic mechanisms,
these data provide further support to our previous
observation (Fig. 3b (ii)) regarding the possible in-
volvement of CID mechanisms by KC-53 action.
Fig. 4 Effects of KC-53 on Caspases and regulatory molecules of the apoptotic pathways in leukemia cells. a Cells were treated with 0 or 5 μΜ
KC-53 for the indicated time points. TNFRs membrane expression levels were analyzed by immunoblotting. EGFR was used as a loading control
and the TNFRs levels were quantified and normalized in comparison to the EGFR levels. b (i) Cells were treated with 0 or 5 μΜ KC-53 for
the indicated time points. (ii) Cells were treated with 0 or 5 μΜ KC-53 in the presence or absence of 20 μM z.vad.fmk. Caspase-8 enzymatic activity was
determined as described in Methods. Etoposide (Eto) added at 5 μΜ was used as a positive control. c (i) Cells were treated with 0 or 5 μΜ KC-53 for
the indicated time points followed by immunoblotting. (ii) Cells were incubated with 0 or 5 μΜ KC-53 for 6 h and cytosolic and nuclear
protein extracts were prepared. The numbers on top of each band represent intensity values and are expressed as fold change in comparison to the
control. The results in panels a, b (i) and c are representative of three repetitions. The results in b (ii) panels represent the mean ± SEM of two
replicates and are representative of three independent experiments. (***p value <0.001)
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of p65/NF-κΒ to the nucleus
TRAF2 is required for the assembly of kinases regulating
the phosphorylation and degradation of the NF-κΒ in-
hibitor, IκBα. We therefore investigated whether KC-53
treatment can affect the downstream molecular events
of the TNFR1/NF-κΒ signalling as well as NF-κΒ trans-
location to the nucleus. This was evaluated by monitor-
ing the phosphorylation status and protein levels of
TRAF2 and IκBα following induction by TNFα in the
absence or presence of KC-53.
We found that TNFα increased the phosphorylation
levels of TRAF2 (Ser11) by 3.5 fold in HL-60 cells and by2.2 fold in CCRF/CEM cells (compared to the control
levels) while KC-53 fully attenuated these effects (Fig. 5a).
Furthermore, in both cell lines, pretreatment with KC-53
fully abolished the TNFα-induced phosphorylation of IκBα
on Ser32/36 without affecting the overall IκBα levels
(Fig. 5a). Nuclear extraction and immunoblotting against
the p65 subunit of NF-κΒ showed a time-depended de-
crease in the TNFα-induced nuclear translocation of p65
in response to KC-53 in both cell lines (Fig. 5b). An im-
pressive 71 % and 82 % decrease in the p65 nuclear levels
in HL-60 and CCRF/CEM cells was noted respectively,
after 6 h of treatment, apparently due to decreased trans-
location. The above findings, clearly show that KC-53
Fig. 5 Effects of KC-53 on TRAF2 and IκΒα phosphorylation, and p65 translocation to the nucleus. a Cells were incubated with vehicle, KC-53 or
PS-341 (for the times indicated) followed by incubation with TNFα for 20 min. Whole cell extracts were analyzed by immunoblotting. b Cells were
incubated to either vehicle, KC-53 or PS-34 as indicated followed by the addition of TNFα for 20 min. The nuclear localization of p65 was examined by
immunoblotting. Histone H3 levels were determined as a loading control and the α-Tubulin levels as an indicator of cytosolic contamination. Numbers
signifies intensity values and are expressed as fold change compared to the control. c Cells were subjected to treatments either with the
vehicle or TNFα (1 ng/ml) for 4 h, or KC-53 (5 μΜ) for 6 h plus TNFα for 4 h. The PCR products were normalized to those obtained from
GAPDH mRNA amplification. The results in panels (a) and (b) are representative of three repetitions. The results in (c) panels represent the mean ± SEM
of two replicates and are representative of three independent experiments. (*p value <0.05, **p value <0.01, ***p value <0.001)
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induced phosphorylation on TRAF2 and IκBα, preventing
in this manner p65 translocation to the nucleus.
The efficiency of KC-53 in inhibiting TRAF2 and IκBα
phosphorylation and/or p65 translocation was also
compared with the well-established proteasome inhibitor,
Bortezomib (PS-341). As was expected, Bortezomib
maintained the IκΒα levels without abolishing the phos-
phorylation on Ser32/36 neither that of TRAF2 on Ser11
(Fig. 5a). Nonetheless Bortezomib reduced p65 nuclear
levels by 83 % compared to the TNFα-treated samples
(Fig. 5b). Thus, the effects of KC-53 on the nuclear levels
of p65 are similar to those of Bortezomib although the
mechanism by which this is achieved is different.
To further test the expectation that KC-53 hinders p65
transcriptional activity, we determined the mRNA levels
of genes known to be transcriptionally activated by p65.
We found that KC-53 robustly inhibited the TNFα-
induced transcription of the pro-inflammatory cytokines;
IL -1β, −6 and −8 and the pro-survival mediators; c-FLIP,
cIAP-1, cIAP-2, BCL-xL and XIAP whereas BCL-2, MCL-1
and Survivin levels were not significantly affected (Fig. 5c).
These results are consistent with the conclusion that KC-53 shifts the balance between the TNFR1-mediated pro-
survival and pro-apoptotic signals in favour of the latter
and thus, inhibits the activation of the NF-κΒ in HL-60
and CCRF/CEM cells. Therefore, the antiproliferative ac-
tivity of KC-53 in leukemia cells might be also attributed
in the inhibition of the NF-κΒ survival axis.
Silencing of FADD protects leukemic cells from KC-53
apoptotic effects
In order to investigate whether KC-53 apoptotic effects
are directly linked to TNFR1 pro-apoptotic signaling
axis we used siRNA for inhibiting the expression of
FADD (Fig. 6a). It is known from previous reports that,
FADD is a core protein of the pro-apoptotic complex
facilitating Caspase-8 activation soon after TNFR1 acti-
vation thus, promoting apoptosis [29]. FADD silencing
significantly restored cell viability by up to 78 and 90 %
in HL-60 and CCRF/CEM respectively (Fig. 6b). These
data suggest that downregulation of FADD confers re-
sistance to KC-53 and that, the cytotoxic effects of the
agent may be mediated through the formation of the
pro-apoptotic complex. In agreement with this, in the
absence of FADD, KC-53 was not able to activate
Fig. 6 Effects of FADD silencing on the antiproliferative and apoptotic properties of KC-53 in leukemic cells. a HL-60 and CCRF/CEM cells were
transiently transfected with siRNA control or siRNA FADD followed by (i) immunoblotting for the detection of FADD protein levels and (ii) qPCR
for measuring FADD mRNA levels. b Transfected cells were treated with 0 or 5 μΜ KC-53 for 24 h and cell viability was determined with the MTT
assay. c Transfected cells were treated with 5 μΜ KC-53 for 6 h and protein levels were determined by immunoblotting. The results in panels a (i)
and c are representative of three repetitions. The results in a (ii) and b panels represent the mean ± SEM of three replicates and are representative of
three separate experiments. (***p value <0.001)
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RIP1 or PARP1 (Fig. 6c). Taken together, the results pre-
sented here support that the FADD/Caspase-8/RIP1
signaling axis plays a crucial role in KC-53 induced
apoptosis of HL-60 and CCRF/CEM cells.
Discussion
Although the overall survival rate of leukemia patients has
dramatically increased in the past decade, there is still a
strong need for discovering new therapeutic agents with
higher specificity and milder side-effects. In the present
study we evaluated for the first time the anticancer effi-
cacy of KC-53. Importantly, we discovered that, KC-53 re-
duces cancer cell viability in a dose-depended manner in
all cell lines and exhibits the highest cytotoxicity towards
HL-60 (AML/APL) and CCR/CEM (ALL) leukemic cell
lines. Remarkably, the normal PBMCs were relatively re-
sistant to the anti-proliferative effects of the agent, sug-
gesting that the KC-53 inhibitory effects are selective
against cancer cells. We show that KC-53 efficiently and
irreversible inhibits cells growth, promoting rabidly CD
and CID apoptotic cell death. The molecular events lead-
ing to reduced survival and apoptosis have been method-
ically unravelled in this study and are illustrated in Fig. 7.
Initially, the agent up-regulates membrane-bound
TNFR1 followed by activation of Caspase-8, RIP1 prote-
olysis and activation of Caspases, −3, −7 and −9. Thefailure of restoring cell viability in the presence of the
pan-caspase inhibitor, z.vad.fmk suggests that CID
mechanisms may also be involved in the mode of action
of KC-53 (Fig. 3b). This prediction is supported by the
release and translocation of AIF from the mitochondrial
to the nucleus (Fig. 4c (ii)) which is commonly induced
by Calpains and Cathepsins [30]. Interestingly, it has
been previously shown that when Caspase-8 activity is
blocked, the cell uses necroptosis as an alternative cell
death pathway (Reviewed in [31]). RIP1 and RIP3 kinase
activities are crucial for this alternative CID pathway in-
duced by death receptors, including TNFR1. Thus, acti-
vation of necroptosis by KC-53 cannot be excluded at
this point.
The participation of FADD in a complex with
Caspase-8 and RIP1 is known to be required for the acti-
vation of the extrinsic pathway through TNFR1 [32].
Down regulation of FADD with siRNA inhibited the for-
mation of the pro-apoptotic complex and, consequently,
the FADD-deficient HL-60 and CCRF/CEM cells devel-
oped resistance to the anti-proliferative and apoptotic ef-
fects of KC-53. These results strongly suggest that,
following TNFR1 activation, one of the primary apop-
totic effects of KC-53 is the formation of the FADD/
Caspsase-8/RIP1 pro-apoptotic complex. Importantly, our
data clearly show that KC-53 concurrently inhibits pro-
survival NF-κΒ signaling. We determined that KC-53
Fig. 7 Sequence of molecular events leading to anti-proliferative and pro-apoptotic effects of KC-53 in leukemic cells. KC-53 stimulates TNFR1
and inhibits TRAF2 phosphorylation. RIP1 dissociates from TRAF2 and binds to the FADD/pro-caspase 8 complex. This leads to the activation of
the procaspase-8 which in turns cleaves and inactivates RIP1. Caspase-8 triggers Bid cleavage, activation of effectors Caspases, −3 and −7 and
inactivation of PARP1 promoting cell apoptosis. tBid leads to Caspase-9 activation and AIF release and translocation to the nucleus. The absence
of RIP1 from TRADD/TRAF2 complex diminishes the phosphorylation of IκΒα by downstream kinases. As a result, IκΒα is not phosphorylated and
fails to be ubiquitinated and degraded by proteasome. Subsequently, NF-κB remains in complex with IκΒα, fails to translocate to the nucleus and
cell survival signaling is hindered. P phosphorylation, ub ubiquitination
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Ser32/36 of IκΒα. The hypo-phosphorylated form of IκΒα
stabilizes the cytoplasmic IκΒα/p65 complex, blocking in
this manner p65 translocation to the nucleus. Conse-
quently, KC-53 TNFα-stimulated gene expression of both
pro-survival and pro-inflammatory p65-mediators. This
effect of KC-53 could also explain the previously reported
anti-inflammatory activity of KC-53 [26].
The use of anti-TNF antibodies and specific agents to
block TNFRs and NF-κB activation has been a valuable
approach against inflammatory diseases [33]. Proteasome
inhibitors [34] and IKK inhibitors [35, 36] have also been
used to block the NF-κB pathway and to enhance the sen-
sitivity of cancer cells to apoptosis. For instance, the prote-
asome inhibitor Bortezomib is currently approved for the
treatment of mantle cell lymphoma [37, 38]. However, due
to low specificity for cancer cells versus normal cells, itcauses severe side effects [37]. The proteasome, which is
responsible for IκΒα degradation has many other vital cel-
lular functions and it may also not be feasible to block it
for prolonged periods. Consequently, hindering NF-κB by
controlling upstream regulatory molecules such as RIP1
and TRAF2 might be a more efficient and less cytotoxic
approach in comparison to Bortezomib for the treatment
of blood diseases. Preclinical evidence for the import-
ance of TRAF2 and RIP1 as targets for anticancer drugs
is based on two observations: (i) that inactivating muta-
tions of TRAF2 is a dominant-negative event, neutraliz-
ing TNFα-induced NF-κB activation [6, 39] and, (ii)
RIP1-null cells or mice do not undergo TNFα-induced
cell death (Reviewed in [40, 41]). Our data revealed
that, KC-53 induced a robust degradation of RIP1 and
dramatically inhibited the TNFα-induced phosphoryl-
ation on Ser11 of TRAF2. As such, the absence of RIP1
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blocked the downstream phosphorylation events lead-
ing to NF-κΒ (space) activation.
Unlike most chemotherapeutic drugs, ligands of the
TNF family induce apoptosis in a p53-independent man-
ner and are promising alternatives to conventional chemo-
therapy. Specifically for leukemia, mutational inactivation
of the p53 gene which mainly regulates apoptosis via the
DNA damage-induced intrinsic pathway, reduces cancer
cell sensitivity to conventional treatments [12, 13]. In this
aspect, KC-53 enables the crosstalk between the extrinsic
and intrinsic pathway enabling cell lines with non-
functional p53 to bypass the p53-mitochondrial block.
Caspase-8-mediated cleavage of Bid provides the link
between death receptor stimulation and mitochondrial
apoptotic events. In both HL-60 (p53−/−) and CCRF/
CEM (p53mut) KC-53 promoted the activation of Bid and
the cleavage of Caspase-9. tBid has the ability to accumu-
late at mitochondria and to initiate MOMP [27]. MOMP
in turn results in the release of pro-apoptotic factors from
the mitochondrial intermembrane space, including cyto-
chrome c, triggering formation of the apoptosome and ac-
tivation of Caspase-9. Collectively, our data identified the
key role of the TNFR1 pathway in KC-53-induced apop-
tosis, where the engagement of the mitochondrial system
amplified cell death. This may have clinical implications,
since it may critically reduce the time required for execu-
tion of the death program. This also suggests that KC-53
may find applications in the treatment of p53 mutant
cancers and help to overcome resistance.
The idea to specifically target the extrinsic pathway to
trigger apoptosis in malignant cells is attractive for can-
cer therapy since death receptors have a direct link to
the death machinery. However, the clinical application of
TNFα and Fas is hampered by severe toxic side effects
[42, 43]. TRAIL remains promising as a cancer thera-
peutic, despite the fact that many tumors remain refrac-
tory towards treatment with TRAIL [44–46]. In most, if
not all, clinical studies the lack of efficacy was probably
attributed to their inability to overcome the mitochon-
drial block [47–49]. KC-53 appears to be a strong candi-
date for TNFR1 activation and may help to overcome
TRAIL resistance and/or increase malignant cell sensi-
tivity to chemotherapy. Our work also represents a new
concept in the design of TNFR1-targeted therapies as
this is the first time that an agent has been reported to
stimulate efficiently TNFR1 inhibiting cancer cell growth
and concurrently eliminate the activation of NF-κB.
Conclusions
Our findings show for the first time that, KC-53 effect-
ively triggers apoptosis by facilitating both the extrinsic
and intrinsic pathway, bypassing the p53-mitochondrial
block and hindering the p65/NF-κB survival cascade inAPL and ALL cells. Because of these qualities we antici-
pate that KC-53 is very likely to find applications, either
as a single agent, or in combination with other conven-
tional chemotherapeutic agents in targeted therapeutics
against acute leukemias.Additional files
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